<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36958743</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1399-3003</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>The European respiratory journal</Title><ISOAbbreviation>Eur Respir J</ISOAbbreviation></Journal><ArticleTitle>Long COVID: clues about causes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2300409</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1183/13993003.00409-2023</ELocationID><Abstract><AbstractText>Many patients report persistent symptoms after resolution of acute COVID-19, regardless of SARS-CoV-2 variant and even if the initial illness is mild [1, 2]. A multitude of symptoms have been described under the umbrella term &#x2018;Long COVID&#x2019;, otherwise known as &#x2018;post-COVID syndrome&#x2019; or &#x2018;post-acute sequelae of SARS-CoV-2 (PASC)&#x2019;; for simplicity we will use the term Long COVID. Symptoms are diverse but include breathlessness, fatigue and brain fog, reported to affect up to 69% of cases [3]. Long COVID can be debilitating, 45.2% of patients requiring a reduced work schedule [4]. The WHO estimates that 17&#x2005;million people in Europe have experienced Long COVID during the first two years of the pandemic [5]. SARS-CoV-2 variants continue to circulate and the risk of post-acute complications remains; a recent study of 56&#x2009;003 UK patients found that even after Omicron infection, 4.5% suffered persistent symptoms [6]. It is therefore likely that Long COVID will provide a substantial medical and economic burden for the foreseeable future. There is an urgent need to understand mechanisms of disease and develop effective treatments based on this understanding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Felicity</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Efstathiou</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6125-8126</Identifier><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Openshaw</LastName><ForeName>Peter J M</ForeName><Initials>PJM</Initials><Identifier Source="ORCID">0000-0002-7220-2555</Identifier><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK p.openshaw@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Respir J</MedlineTA><NlmUniqueID>8803460</NlmUniqueID><ISSNLinking>0903-1936</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Eur Respir J. 2023 May 11;61(5):2202226. doi: 10.1183/13993003.02226-2022</RefSource><PMID Version="1">36922030</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of interest: P.J.M. Openshaw reports grants from the EU Innovative Medicines Initiative (IMI) 2 Joint Undertaking during the submitted work; grants from UK Medical Research Council, GlaxoSmithKline, Wellcome Trust, EU-IMI, UK, National Institute for Health Research, and UK Research and Innovation-Department for Business, Energy and Industrial Strategy, and personal fees from Pfizer, Nestle, Janssen and Seqirus, outside the submitted work. F. Liew, C. Efstathiou and P.J.M. Openshaw are members of the PHOSP-COVID consortia, a UK-wide study examining long-term health outcomes after hospitalisation with COVID-19.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>20</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36958743</ArticleId><ArticleId IdType="pmc">PMC10040855</ArticleId><ArticleId IdType="doi">10.1183/13993003.00409-2023</ArticleId><ArticleId IdType="pii">13993003.00409-2023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. . Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 2023; 380: e072529. doi:10.1136/bmj-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. . Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med 2021; 9: 1275&#x2013;1287. doi:10.1016/S2213-2600(21)00383-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4: e2128568. doi:10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019. doi:10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Covid-19: WHO urges action as 17 million long covid cases are estimated in Europe. BMJ 2022; 378: o2232. doi:10.1136/bmj.o2232</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o2232</ArticleId><ArticleId IdType="pubmed">36104031</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al. . Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022; 399: 2263&#x2013;2264. doi:10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, et al. . Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 2023; 29: 226&#x2013;235. doi:10.1038/s41591-022-02116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133&#x2013;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia L, Sperandio M, Yago T, et al. . P-selectin glycoprotein ligand-1&#x2013;deficient mice have impaired leukocyte tethering to E-selectin under flow. J Clin Invest 2002; 109: 939&#x2013;950. doi:10.1172/JCI0214151</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0214151</ArticleId><ArticleId IdType="pmc">PMC150926</ArticleId><ArticleId IdType="pubmed">11927621</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan AJ, Guillen C, Symon FA, et al. . Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. Clin Exp Allergy 2005; 35: 1572&#x2013;1580. doi:10.1111/j.1365-2222.2005.02383.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2222.2005.02383.x</ArticleId><ArticleId IdType="pubmed">16393323</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol 2015; 15: 511&#x2013;523. doi:10.1038/nri3859</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3859</ArticleId><ArticleId IdType="pmc">PMC4606863</ArticleId><ArticleId IdType="pubmed">26139350</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppe AEF, Edelmann MJ. Roles of eicosanoids in regulating inflammation and neutrophil migration as an innate host response to bacterial infections. Infect Immun 2021; 89: e0009521. doi:10.1128/IAI.00095-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00095-21</ArticleId><ArticleId IdType="pmc">PMC8281227</ArticleId><ArticleId IdType="pubmed">34031130</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight R, Walker V, Ip S, et al. . Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. Circulation 2022; 146: 892&#x2013;906. doi:10.1161/CIRCULATIONAHA.122.060785</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.060785</ArticleId><ArticleId IdType="pmc">PMC9484653</ArticleId><ArticleId IdType="pubmed">36121907</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldobaeva A, van Rooijen N, Wagner EM. Effects of ischemia on lung macrophages. PLoS One 2011; 6: e26716. doi:10.1371/journal.pone.0026716</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026716</ArticleId><ArticleId IdType="pmc">PMC3217923</ArticleId><ArticleId IdType="pubmed">22110592</ArticleId></ArticleIdList></Reference><Reference><Citation>Grist JT, Chen M, Collier GJ, et al. . Hyperpolarized 129 Xe MRI abnormalities in dyspneic patients 3 months after COVID-19 pneumonia: preliminary results. Radiology 2021; 301: E353&#x2013;E360. doi:10.1148/radiol.2021210033</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021210033</ArticleId><ArticleId IdType="pmc">PMC8168952</ArticleId><ArticleId IdType="pubmed">34032513</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Trefry JC, Babka AM, et al. . Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. Sci Transl Med 2022; 14: eabi5229. doi:10.1126/scitranslmed.abi5229</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi5229</ArticleId><ArticleId IdType="pubmed">35138912</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. . 
Evolution of antibody immunity to SARS-CoV-2. Nature
2021; 591: 639&#x2013;644. www.nature.com/articles/s41586-021-03207-w doi:10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani R, Zentilin L, Correa R, et al. . Persistent SARS-CoV -2 infection in patients seemingly recovered from COVID -19. J Pathol 2023; 259: 254&#x2013;263. doi:10.1002/path.6035</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.6035</ArticleId><ArticleId IdType="pmc">PMC10107739</ArticleId><ArticleId IdType="pubmed">36651103</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. . 
Distinguishing features of Long COVID identified through immune profiling. medRxiv 2022; www.medrxiv.org/content/early/2022/08/10/2022.08.09.22278592</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau T-M, Munter SE, et al. . Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest 2023; 133: e163669. doi:10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (1979) 2020; 370: eabd4585. doi:10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. . 
Distinguishing features of Long COVID identified through immune profiling. medRxiv
2022; http://medrxiv.org/content/early/2022/08/10/2022.08.09.22278592.abstract</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185: 881&#x2013;895.e20. doi:10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponce MC, Sankari A, Sharma S. Pulmonary Function Tests. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">29493964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>